Dorsal hyperintensity and iron deposition patterns in the substantia nigra of Parkinson’s disease, idiopathic REM sleep behavior disorder, and Parkinson-plus syndromes at 7T MRI: a prospective diagnostic study.

Publication date: Jul 04, 2025

Dorsal nigral hyperintensity (DNH) abnormality associated with excessive iron deposition in the substantia nigra, is recognized as an imaging characteristic of Parkinson’s disease (PD) and can be effectively visualized using 7T MRI. This study was aimed to develop and validate the optimal DNH assessment method as a biomarker for PD, idiopathic rapid eye movement sleep behavior disorder (iRBD), and Parkinson-plus syndromes, and to explore the nigral iron deposition patterns in these diseases. Three-dimensional gradient-echo T2*-weighted images were acquired by 7T MRI from a total of 402 patients and 100 healthy controls (HCs) in two independent cohorts (development and validation cohorts). Seven methods, including four dichotomous methods and three DNH rating scales, were used to assess DNH and evaluate their diagnostic performance. R2* mapping and principal component analysis were performed to assess nigral iron deposition patterns. Bilateral DNH detection rates in the development cohort were 22. 6% for early-stage PD, 3. 7% for advanced PD, 93. 5% for iRBD, 5. 7% for MSA-parkinsonian type, 78. 8% for MSA-cerebellar type, 11. 8% for progressive supranuclear palsy (PSP), and 100% for HC, with similar rates in the validation cohort. A cut-off of 6 on the 6-point visibility scale demonstrated a 100% accuracy for diagnosing early-stage PD in both the development and the validation cohorts. This scale exhibited moderate differential diagnostic performance between early-stage PD and iRBD (area under the curve [AUC] = 0. 940) or MSA-C (AUC = 0. 892). Iron deposition was predominantly in the dorsal and posterior substantia nigra of PD and PSP, the intermediate and posterior substantia nigra of MSA-P, and the ventral substantia nigra of MSA-C. DNH may be preserved in approximately one-quarter of early-stage PD and most MSA-C cases. The 6-point visibility scale on 7T effectively distinguished PD from HC, iRBD, and MSA-C. The nigral iron deposition pattern in PD may help distinguish PD from MSA-P and MSA-C, although it overlaps with that of PSP.

Open Access PDF

Concepts Keywords
Healthy 7T MRI
Mri Dorsal nigral hyperintensity
Nigra Iron deposition
Parkinsonian Parkinson-plus syndromes
Parkinson’s disease
Substantia nigra

Semantics

Type Source Name
drug DRUGBANK Iron
disease MESH Parkinson’s disease idiopathic
disease MESH REM sleep behavior disorder
disease MESH syndromes
drug DRUGBANK Flunarizine
disease MESH progressive supranuclear palsy
disease MESH palsy
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
drug DRUGBANK Indoleacetic acid
disease MESH multiple system atrophy
drug DRUGBANK Pidolic Acid
disease MESH Movement Disorder
disease MESH Sleep Disorders
disease MESH dementia
disease MESH secondary parkinsonism
drug DRUGBANK Dopamine
disease MESH parkinsonism
disease MESH cerebrovascular disease
disease MESH epilepsy
disease MESH brain tumor
disease MESH psychiatric disorder
disease MESH contraindications
disease MESH claustrophobia
disease MESH tremor
disease MESH dyskinesia
disease MESH Anxiety
drug DRUGBANK Albendazole
drug DRUGBANK Saquinavir
drug DRUGBANK Trestolone
disease MESH atrophy
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Proline
disease MESH synucleinopathies
disease MESH neurodegenerative disease
drug DRUGBANK L-Citrulline
pathway REACTOME Neurodegenerative Diseases
disease MESH neuron degeneration
disease MESH iron overload
drug DRUGBANK Fenamole
drug DRUGBANK Dansyllysine
drug DRUGBANK Esomeprazole
drug DRUGBANK Piroxicam
pathway KEGG Parkinson disease
drug DRUGBANK Water
drug DRUGBANK Sulpiride
disease MESH Lewy body dementia
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK Troleandomycin
pathway REACTOME Glucose metabolism
disease MESH Wilson’s disease
drug DRUGBANK Quinine

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *